JNJ

225.79

-1.76%↓

UNH

368.46

+1.13%↑

TMO

466.31

-0.53%↓

ISRG

450.18

-3.39%↓

ABT

92.06

-1.82%↓

JNJ

225.79

-1.76%↓

UNH

368.46

+1.13%↑

TMO

466.31

-0.53%↓

ISRG

450.18

-3.39%↓

ABT

92.06

-1.82%↓

JNJ

225.79

-1.76%↓

UNH

368.46

+1.13%↑

TMO

466.31

-0.53%↓

ISRG

450.18

-3.39%↓

ABT

92.06

-1.82%↓

JNJ

225.79

-1.76%↓

UNH

368.46

+1.13%↑

TMO

466.31

-0.53%↓

ISRG

450.18

-3.39%↓

ABT

92.06

-1.82%↓

JNJ

225.79

-1.76%↓

UNH

368.46

+1.13%↑

TMO

466.31

-0.53%↓

ISRG

450.18

-3.39%↓

ABT

92.06

-1.82%↓

Search

Bridgebio Pharma Inc

Open

SectorGezondheidszorg

70.92 -3.26

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

68.19

Max

71.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-7.5M

-190M

Verkoop

33M

154M

Winstmarge

-123.403

Werknemers

834

EBITDA

-6.9M

-180M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+50.04% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

14B

Vorige openingsprijs

74.18

Vorige sluitingsprijs

70.92

Nieuwssentiment

By Acuity

30%

70%

95 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2026, 23:33 UTC

Populaire aandelen

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr 2026, 23:24 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr 2026, 22:46 UTC

Winsten

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr 2026, 22:37 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr 2026, 22:15 UTC

Winsten
Belangrijke Nieuwsgebeurtenissen

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr 2026, 23:19 UTC

Marktinformatie
Winsten

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr 2026, 23:09 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr 2026, 23:03 UTC

Marktinformatie

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr 2026, 22:51 UTC

Winsten

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr 2026, 22:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 apr 2026, 22:48 UTC

Marktinformatie

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr 2026, 22:40 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr 2026, 22:32 UTC

Winsten

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr 2026, 22:22 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr 2026, 22:17 UTC

Marktinformatie

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

50.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 104.59 USD  50.04%

Hoogste 157 USD

Laagste 81 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

18

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

95 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat